These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 6223590)

  • 1. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
    Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer--double-blind controlled study: Japanese Group for MPA Treatment of Breast Cancer].
    Izuo M; Tominaga T; Yoshida M; Nomura Y; Abe O; Enomoto K; Kubo K; Takatani O
    Gan No Rinsho; 1985 May; 31(5):487-93. PubMed ID: 3160869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral high-dose medroxyprogesterone acetate treatment for recurrent breast cancer.
    Iino Y; Takeo T; Sugamata N; Aoyagi H; Takai Y; Takei H; Ando T; Koibuchi Y; Yokoe T; Ohwada S
    Anticancer Res; 1995; 15(3):1061-4. PubMed ID: 7645926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic effects of medroxyprogesterone acetate in recurrent or advanced breast cancer].
    Yoshida M; Murai H; Miura S
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):516-23. PubMed ID: 3159345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Phase II study of medroxyprogesterone acetate in advanced breast cancer].
    Ueno K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nakamura T; Ito Y; Imajo K; Ozeki H
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3198-202. PubMed ID: 2946264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A controlled study with medroxyprogesterone acetate (MPA) alone or in combination with cyclophosphamide (CPA) in the treatment of advanced or recurrent breast cancer unresponsive to other therapies. Osaka Study Group for the Treatment of Breast Cancer].
    Aikawa T; Yayoi E; Takatsuka Y; Maeura Y; Miyauchi K
    Gan To Kagaku Ryoho; 1991 May; 18(6):995-1002. PubMed ID: 1827575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on CAF + medroxyprogesterone acetate (MPA) therapy for advanced or recurrent breast cancer--comparison between MPA 600 mg and 1,200 mg. Kyushu CAFT Therapy Study Group (Third Study)].
    Mitsuyama S; Ohno S; Koga T; Takayama T; Yamashita J; Ogawa M; Shirouzu K; Sugimachi K; Nomura Y; Ogawa N
    Gan To Kagaku Ryoho; 1999 Nov; 26(13):2029-36. PubMed ID: 10584567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
    Nomura Y; Tashiro H; Hisamatsu K; Toi M
    Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A comparative study between low-dose and high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer--in relation to dose, serum concentration and response. Osaka Breast Cancer Research Group].
    Furukawa J; Yayoi E; Takatsuka Y; Aikawa T; Maeura Y; Kobayashi T; Miyauchi K; Kotsuma Y
    Gan To Kagaku Ryoho; 1997 May; 24(7):815-21. PubMed ID: 9170519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
    Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
    Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
    Pannuti F; Longhi A; Martoni A; Piana E; Baroni M
    Chemioterapia; 1987 Dec; 6(6):396-8. PubMed ID: 2963702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer].
    Noguchi S; Yamamoto H; Inaii H; Koyama H
    Gan To Kagaku Ryoho; 1989 Nov; 16(11):3555-8. PubMed ID: 2530936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effectiveness of combination hormonal therapies in advanced or recurrent breast cancer--a randomized trial of tamoxifen (TAM), medroxyprogesterone acetate (MPA), their simultaneous combination, and an alternating sequential combination of TAM plus MPA].
    Sonoo H; Senoo T; Nishiki M; Morimoto T; Takashima S
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):447-54. PubMed ID: 8678496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical trial of high-dose medroxyprogesterone acetate in advanced breast cancer].
    Jiang Z; Song S; Li J
    Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):71-3. PubMed ID: 7656795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.
    Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J
    Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
    Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P
    Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced phases of breast and endometrial cancer].
    Bernardo-Strada MR; Imparato E; Aspesi G; Pavesi L; Robustelli Della Cuna G
    Minerva Med; 1980 Nov; 71(44):3241-6. PubMed ID: 7454090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemo-endocrine therapy with high dose medroxyprogesterone acetate for recurrent or advanced breast cancer].
    Maeda T; Kubo Y; Sasajima T; Ikeda K; Hirata S; Yamazaki K; Nakajima S
    Gan To Kagaku Ryoho; 1993 Nov; 20(14):2165-9. PubMed ID: 8239681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers].
    Wada T; Matunami N; Houjou T; Morikawa E; Mori N; Nakano K; Aizawa M; Kurooka K; Kadota K; Yamato M
    Gan To Kagaku Ryoho; 1989 May; 16(5):2087-92. PubMed ID: 2525004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
    Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
    Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.